An independent report on the US Food and Drug Administration’s COVID-19 response is spurring the agency to make some changes intended to improve how it handles emergency use authorization applications and communicates with industry.
The “FDA COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) Initiative: Summary Report” was presented to the agency back in January, although it wasn’t until 2 April that the agency...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?